EN DE
Watch Pharmacielo Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Pharmacielo Ltd (PCLO) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Pharmacielo Ltd stock C$0.05, price C$0.05, that is 0.0% below the price, quality 34 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · ISIN CA71716K1012

PL Pharmacielo Ltd logo Thin data Nov 10, 2026

Pharmacielo Ltd

PCLO · V
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value C$0.0500 · Fairly valued
Mixed Growth (revenue 5y +34.6 %/yr in CAD)
Negative equity (buybacks among others)
Revenue last quarter 46% below a year ago.
Quality 34/100
Negative free cash flow
Trails peers (1/5)
Narrow moat 23/100
Thin data
Estimate⚠ Thinly traded
Watch Pharmacielo Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$1.48 C$0.0350 Fair Value C$0.0500 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range C$0.0350 – C$1.48 · fair‑value band C$0.0437 – C$0.0563 · the C$0.0500 price screens above the C$0.0500 fair value. As of Nov 10, 2026.

Follow Pharmacielo in your weekly email

Every Wednesday you see whether Pharmacielo is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada.

Show moreShow less

The company's products include medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its products.

It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies. PharmaCielo Ltd. is headquartered in Toronto, Canada.

Stock analysis

Pharmacielo Ltd (PCLO) currently trades at C$0.0500, while our estimate is C$0.0500, so the stock looks roughly fairly valued today (gap 0.0%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: C$0.0437 (bear) to C$0.0563 (bull), the price of C$0.0500 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Pharmacielo Ltd reported revenue of C$3.5M in FY2024 versus C$2.7M in FY2020, a compound +7.0%/yr. Reported net income was −C$9.1M in FY2024.

Key figures

Market cap C$10.0M (≈ $7.1M) Micro · P/S ratio 11.3 · EPS (TTM) C$−0.0500 · Return on equity −3,013% · Return on assets (EBIT) −57.2% (5-year average) · Operating margin 262% · Revenue (TTM) C$1.8M · Revenue growth (YoY) −46.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 63% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 0%, PCLO screens cheaper than that median.

Fair Value

Bear C$0.0437 Fair Value C$0.0500 Bull C$0.0563
Price C$0.0500 · Downside -0.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 1
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 49
How calm the share price moves, does not count
Price momentum 40
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 28
Distance to the 52-week high, does not count
New shares 28
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+125.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4,316.1% (2019) → −140.9% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

Watch PCLO, get fair value alerts →

Compare Pharmacielo Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside +0.0% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −49.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −46.2% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 5.71× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 31

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs PCLO
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs PCLO
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs PCLO
Haleon plc HLN $9.06 $8.62 −5% vs PCLO
Merck KGaA MRK €149.35 €109.18 −27% vs PCLO
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs PCLO
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs PCLO
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs PCLO
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs PCLO
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs PCLO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pharmacielo Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pharmacielo Ltd Fair Value". https://www.fairvalue-calculator.com/stock/PCLO

Frequently asked questions

Is Pharmacielo Ltd (PCLO) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is C$0.0500 versus a price of C$0.0500, about 0% lower (fairly valued).
What is the fair value of PCLO?
Our estimate for Pharmacielo Ltd is C$0.0500 (as of Nov 10, 2026), built from audited fundamentals. The current price: C$0.0500.
What is the quality score of PCLO?
Pharmacielo Ltd has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharmacielo Ltd (PCLO)?
Our calculated price target is the estimate of C$0.0500 (as of Nov 10, 2026). Cautious scenario C$0.0437, optimistic scenario C$0.0563. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Pharmacielo Ltd stock forecast for 2026?
Our estimate puts fair value at C$0.0500, about 0% lower versus a price of C$0.0500 (fairly valued). Cautious scenario C$0.0437, optimistic scenario C$0.0563. The calculation is refreshed regularly with new filings.
What is the revenue of Pharmacielo Ltd (PCLO)?
Pharmacielo Ltd reported trailing-twelve-month revenue of about C$1.8M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Pharmacielo Ltd (PCLO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharmacielo Ltd it is C$0.0500 per share (as of Nov 10, 2026), against a price of C$0.0500.
Is Pharmacielo Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PCLO trades above its calculated fair value: price C$0.0500, fair value C$0.0500, a gap of about −0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PCLO?
No. The price is what the market pays today (C$0.0500); the fair value is what the company's own numbers justify (C$0.0500). For Pharmacielo Ltd the two are C$0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharmacielo Ltd worth?
The market values Pharmacielo Ltd at about C$10.0M (market capitalisation, as of Nov 10, 2026). Per share that is C$0.0500; our models calculate a fair value of C$0.0500 per share.
What do the bullish and bearish scenarios say about PCLO?
Our models span a range for Pharmacielo Ltd: cautious scenario C$0.0437, base C$0.0500, optimistic C$0.0563 per share (as of Nov 10, 2026, price C$0.0500). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pharmacielo Ltd (PCLO)?
Balance-sheet figures for Pharmacielo Ltd (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is PCLO from its 52-week high?
Pharmacielo Ltd trades at C$0.0500, about 63% below its 52-week high of C$0.1350 and 25% above the low of C$0.0400 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.0500 is for.
Which stocks are comparable to Pharmacielo Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharmacielo Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price C$0.0500, calculated fair value C$0.0500 (−0%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Pharmacielo Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharmacielo Ltd (PCLO)?
The closing price on Nov 10, 2026 was C$0.0500. Our estimate is C$0.0500, about 0% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharmacielo Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Pharmacielo Ltd

How large is the market capitalisation of Pharmacielo Ltd (PCLO)?
The market capitalisation of Pharmacielo Ltd is C$10.0M (≈ $7.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharmacielo Ltd (PCLO)?
The price-to-sales ratio of Pharmacielo Ltd is 11.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pharmacielo Ltd (PCLO)?
Earnings per share at Pharmacielo Ltd are C$−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Pharmacielo Ltd (PCLO)?
The return on equity (ROE) of Pharmacielo Ltd is −3,013% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharmacielo Ltd (PCLO)?
On an EBIT basis the return on assets of Pharmacielo Ltd is −57.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharmacielo Ltd (PCLO)?
The operating margin of Pharmacielo Ltd is 262% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharmacielo Ltd (PCLO)?
Revenue at Pharmacielo Ltd is growing −46.2% versus a year earlier (3y avg +21.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pharmacielo Ltd (PCLO) generate?
The free cash flow of Pharmacielo Ltd is −C$2.0M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pharmacielo Ltd (PCLO) carry?
The net debt of Pharmacielo Ltd is C$20.4M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pharmacielo Ltd in the live analysis

One click puts Pharmacielo Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.